Silence, page-20

sg, You have identified the waste of time and how unprofitable it has been to obfuscate the reality of lack of execution and honest communication when it really counts.

Shareholders have spoken silently but meaningfully by getting out. What was plainly seen by the institutions and funds who started selling three years ago following the inability to prove PBT2's benefit for AD and the resulting dramatic sell-off and continued losses have been followed by the steady selling by retail investors. That was brought to a head this year when the company did not provide data to the FDA in early 2016 as they had guided last year after many months of inactivity. No reasonable explanation was given and executive follow-up has continued to be sorely lacking.

Here's the point: Present and future outlook for sufficient financial support looks bleak. Cash has dwindled and plans to raise at the ATM will not produce what it could have in better times. There is less chance now, if any, of collaborative partnership with substantial successful biopharmas.

Still now unknowing posters write of such things as eight unnamed trials and fail to admit that no Prana product has made it to market in nearly two decades. The blame for that is ridiculously placed outside of the company.

The Annual General Meeting is coming up. The meeting room should be packed with thoughtful questioning shareholders who are not on the agenda. Unfortunately that will be too little and much too late.